Abstract Depressive disorders exhibit significant comorbidity with lipid dysregulation
doi:10.1093/ajcn/48.3.852
Symptoms are most pronounced during the initial weeks of treatment and following dose escalations, as the body adjusts to the medication's effects on gastric motility
An analysis was conducted to compare age, BMI, fat percentage, fat and muscle mass, VFR, fasting glucose and glucose after 2-hour glucose tolerance test, baseline insulin, baseline GLP-1, HOMAB%, HOMA IR and HOMA 2S between the two groups
Importantly, this tolerance window doesn't mean the medication stops workingappetite suppression and weight loss benefits actually improve during weeks two through twelve as your body adjusts